Tech Company Financing Transactions
PrEP Biopharm Funding Round
PrEP Biopharm, based in London, secured $32.5 million from hVIVO and private investors.
Transaction Overview
Company Name
Announced On
11/3/2015
Transaction Type
Venture Equity
Amount
$32,480,000
Round
Series A
Investors
hVIVO (Lead Investor) (Kym Denny)
Proceeds Purpose
PrEP Biopharm will use the funds to complete ongoing phase 2a development of its lead compound, PrEP-001.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20-22 Bedford Row
London, WC1R 4JS
UK
London, WC1R 4JS
UK
Phone
Undisclosed
Email Address
Not Recorded
Overview
PrEP Biopharm Limited is a development stage biopharmaceutical company focused on the prevention of respiratory infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kym Denny
Browse more venture capital transactions:
Prev: 11/3/2015: Everactive venture capital transaction
Next: 11/3/2015: Weave venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs